CAR-T (Autoimmune) vs Monoclonal Antibody — Immunology Deal Terms Comparison
Market Analysis
In immunology, CAR-T (Autoimmune) and Monoclonal Antibody represent two of the most actively transacted modalities. At Phase 2, CAR-T (Autoimmune) deals carry a median total deal value of $5.0B with $914M upfront, compared to $2.5B total value and $480M upfront for Monoclonal Antibody. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. CAR-T (Autoimmune) development milestones average $820M versus $405M for Monoclonal Antibody. Commercial milestones are $1.8B for CAR-T (Autoimmune) and $911M for Monoclonal Antibody. Royalty rates range from 16.3%-27.2% for CAR-T (Autoimmune) and 13.2%-22.1% for Monoclonal Antibody.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do CAR-T (Autoimmune) and Monoclonal Antibody deal terms compare in immunology?
Which modality commands higher royalty rates: CAR-T (Autoimmune) or Monoclonal Antibody?
How do milestone structures differ between CAR-T (Autoimmune) and Monoclonal Antibody?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.